JP2018525345A - 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 - Google Patents

置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 Download PDF

Info

Publication number
JP2018525345A
JP2018525345A JP2017568029A JP2017568029A JP2018525345A JP 2018525345 A JP2018525345 A JP 2018525345A JP 2017568029 A JP2017568029 A JP 2017568029A JP 2017568029 A JP2017568029 A JP 2017568029A JP 2018525345 A JP2018525345 A JP 2018525345A
Authority
JP
Japan
Prior art keywords
group
compound
alkyl
glucocerebrosidase
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525345A5 (enExample
Inventor
クラインク ディミトリ
クラインク ディミトリ
ビー．シルバーマン リチャード
ビー．シルバーマン リチャード
チエンピン チョン
チエンピン チョン
Original Assignee
ノースウェスタン ユニバーシティ
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ, ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2018525345A publication Critical patent/JP2018525345A/ja
Publication of JP2018525345A5 publication Critical patent/JP2018525345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017568029A 2015-07-01 2016-06-30 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 Pending JP2018525345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187461P 2015-07-01 2015-07-01
US62/187,461 2015-07-01
PCT/US2016/040467 WO2017004405A1 (en) 2015-07-01 2016-06-30 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity

Publications (2)

Publication Number Publication Date
JP2018525345A true JP2018525345A (ja) 2018-09-06
JP2018525345A5 JP2018525345A5 (enExample) 2019-08-08

Family

ID=57609612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568029A Pending JP2018525345A (ja) 2015-07-01 2016-06-30 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用

Country Status (5)

Country Link
US (3) US10167270B2 (enExample)
EP (1) EP3317265A4 (enExample)
JP (1) JP2018525345A (enExample)
CN (1) CN108290855A (enExample)
WO (1) WO2017004405A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517789A (ja) * 2021-04-30 2024-04-23 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
JP2024539628A (ja) * 2021-10-13 2024-10-29 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用
JP2024539655A (ja) * 2021-10-13 2024-10-29 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215511B1 (en) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3380469B1 (en) * 2015-11-25 2022-03-16 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
MX388912B (es) 2016-04-06 2025-03-20 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
AU2017311047B2 (en) 2016-08-08 2021-07-22 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
SG11202100818RA (en) * 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
KR20210110566A (ko) * 2018-10-16 2021-09-08 이케나 온콜로지, 인코포레이티드 인돌 ahr 저해제 및 이의 용도
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
US20240166669A1 (en) * 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
TW202509030A (zh) * 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2026020056A1 (en) * 2024-07-18 2026-01-22 Neumora Therapeutics, Inc. Compounds and methods for treating neurological disorders

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2623878A (en) * 1948-02-09 1952-12-30 Ciba Pharm Prod Inc 2, 4-disubstituted amino quinazolines
US2940844A (en) * 1955-12-21 1960-06-14 Geigy Ag J R Compositions and method for inhibiting the growth of plants
JPS5417123A (en) * 1977-06-07 1979-02-08 Sankyo Co Ltd Agricultural and horticultural microbicide
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
JP2009519995A (ja) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
US20130072477A1 (en) * 2002-12-04 2013-03-21 Mitsubishi Tanabe Pharma Coporation Treatment of parkinson's disease and enhancement of dopamine signal using pde 10 inhibitor
JP2014503528A (ja) * 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
US20150159134A1 (en) * 2013-12-11 2015-06-11 Pfizer Limited Method for producing retinal pigment epithelial cells
KR20150065157A (ko) * 2013-12-04 2015-06-12 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
WO2015093551A1 (ja) * 2013-12-18 2015-06-25 出光興産株式会社 化合物、有機エレクトロルミネッセンス素子用材料、インク組成物、有機エレクトロルミネッセンス素子、電子機器、及び化合物の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003299A (en) 1910-08-06 1911-09-12 Basf Ag Process and apparatus for producing long stable electric arcs.
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
WO2017004408A1 (en) 2015-07-01 2017-01-05 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
CN108290855A (zh) 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2623878A (en) * 1948-02-09 1952-12-30 Ciba Pharm Prod Inc 2, 4-disubstituted amino quinazolines
US2940844A (en) * 1955-12-21 1960-06-14 Geigy Ag J R Compositions and method for inhibiting the growth of plants
JPS5417123A (en) * 1977-06-07 1979-02-08 Sankyo Co Ltd Agricultural and horticultural microbicide
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US20130072477A1 (en) * 2002-12-04 2013-03-21 Mitsubishi Tanabe Pharma Coporation Treatment of parkinson's disease and enhancement of dopamine signal using pde 10 inhibitor
JP2009519995A (ja) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2014503528A (ja) * 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
KR20150065157A (ko) * 2013-12-04 2015-06-12 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
US20150159134A1 (en) * 2013-12-11 2015-06-11 Pfizer Limited Method for producing retinal pigment epithelial cells
WO2015093551A1 (ja) * 2013-12-18 2015-06-25 出光興産株式会社 化合物、有機エレクトロルミネッセンス素子用材料、インク組成物、有機エレクトロルミネッセンス素子、電子機器、及び化合物の製造方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"CAS REGISTRY NO. 1288842-33-0", DATABASE REGISTRY, [ONLINE], JPN7020001572, 1 May 2011 (2011-05-01), ISSN: 0004452858 *
"CAS REGISTRY NO. 1294871-00-3", DATABASE REGISTRY, [ONLINE], JPN7020001574, 15 May 2011 (2011-05-15), ISSN: 0004452860 *
"CAS REGISTRY NO. 1295237-43-2", DATABASE REGISTRY, [ONLINE], JPN7020001573, 15 May 2011 (2011-05-15), ISSN: 0004452859 *
"CAS REGISTRY NO. 1318718-96-5", DATABASE REGISTRY, [ONLINE], JPN7020001575, 16 August 2011 (2011-08-16), ISSN: 0004452861 *
LEE, SJ ET AL.: "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, JPN6020020182, 1995, pages 3547 - 3557, ISSN: 0004452855 *
MARUGAN, JJ ET AL.: "Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, JPN6020020184, 2011, pages 1033 - 1058, ISSN: 0004452856 *
PATNAIK, S ET AL.: "Discovery, Structure-Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecul", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, JPN6020020189, 2012, pages 5734 - 5748, ISSN: 0004282962 *
ROTHMAN, RB ET AL.: "Studies of the Biogenic Amine Transporters. 13. Identification of "Agonist" and "Antagonist" Alloste", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 329, JPN6020020185, 2009, pages 718 - 728, ISSN: 0004452857 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517789A (ja) * 2021-04-30 2024-04-23 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
JP2024539628A (ja) * 2021-10-13 2024-10-29 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用
JP2024539655A (ja) * 2021-10-13 2024-10-29 ヴァンキア バイオ，インコーポレイテッド グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用

Also Published As

Publication number Publication date
US20170001976A1 (en) 2017-01-05
US10934270B2 (en) 2021-03-02
WO2017004405A1 (en) 2017-01-05
CN108290855A (zh) 2018-07-17
US10501435B2 (en) 2019-12-10
EP3317265A4 (en) 2019-04-17
US20200071292A1 (en) 2020-03-05
US10167270B2 (en) 2019-01-01
EP3317265A1 (en) 2018-05-09
US20190062303A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US10934270B2 (en) Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
US10442812B2 (en) Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US12291533B2 (en) Substituted fused pyrimidine compounds and uses thereof
US10882865B2 (en) Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
EA017726B1 (ru) Индолы в качестве модуляторов никотинового рецептора ацетилхолина подтипа альфа-7
KR20180022661A (ko) 신경퇴행성 질환을 치료하는 방법
CN108558831A (zh) 取代吡咯-4-烷基胺类化合物及其用途
EP1650206A1 (en) Phenylazole compounds, production process, and antioxidants
TW202425994A (zh) 用於靶向降解雄激素受體之化合物及方法
CN117551073A (zh) 用于治疗皮肤疾病噻吩基苯胺化合物
DE19756036A1 (de) Amid- und Harnstoffderivate
Agatonovic-Kustrin et al. Compatibility studies between mannitol and omeprazole sodium isomers
CN116056698B (zh) 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
AU2019223036B2 (en) Indole and benzimidazole derivatives as dual 5-HT2a and 5-HT6 receptor antagonists
CA2917490A1 (en) Heterocyclic compound
KR20000029564A (ko) 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물
Liu et al. Synthesis of 2-(4-substitutedmethylpiperazin-1-yl)-N-(3, 4-dihydro-3-oxo-2H-benzo [b][1, 4] oxazin-7-yl) acetamides and their positive inotropic evaluation
KR20240066906A (ko) 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
CN119330964A (zh) 吡咯并吡啶类杂环化合物及其制备方法和制备治疗阿尔茨海默病的药物中的应用
HK1227869A1 (en) Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210302